Ascentage Pharma’s 2022 Revenue Soars with Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) has announced its 2022 financial results, marking the first year...
HKG: 6855
Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...
Ascentage Pharma Receives Drug Production License for Suzhou Plant
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following...
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
Ascentage Pharma Presents APG-1387 Phase I Study Results at AASLD
Hong Kong-based biotech Ascentage Pharma (HKG: 6855) presented the Phase I clinical study results of...
Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH
Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...
Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...
Ascentage Pharma’s H1 2022 Revenue Surges 636.9% on Olverembatinib Sales
China-based Ascentage Pharma (HKG: 6855) reported a significant increase in revenue for the six months...
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...
Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...